创新药行情或随时重启！早盘V型大反转，高弹性港股通创新药ETF（520880）迅速拉升逾3%

Group 1 - The core viewpoint of the news is that the Hong Kong innovative drug sector is experiencing a strong rebound, with significant capital inflow into the Hong Kong Innovative Drug ETF (520880), which saw a peak increase of over 3% during trading [1] - As of October 31, the Hong Kong Innovative Drug ETF (520880) has attracted nearly 250 million yuan in the last 10 days, indicating strong investor interest [1] - The fund manager, Feng Chen, suggests that the innovative drug market may soon see renewed momentum due to reduced geopolitical risks following a meeting between US and Chinese leaders, which could encourage previously cautious investors to re-enter the market [1] Group 2 - The Hong Kong Innovative Drug ETF (520880) passively tracks the Hang Seng Hong Kong Innovative Drug Selected Index, which exclusively includes innovative drug R&D companies and has over 70% of its holdings in large-cap innovative drug leaders [2] - As of the end of September, the index has achieved a year-to-date increase of 108.14%, outperforming other innovative drug indices [2] - The latest fund size of the Hong Kong Innovative Drug ETF (520880) is 1.967 billion yuan, with an average daily trading volume of 469 million yuan since its inception, making it the largest and most liquid ETF in its category [2]